Orbimed Advisors LLC Passage Bio, Inc. Transaction History
Orbimed Advisors LLC
- $4.15 Billion
- Q2 2024
A detailed history of Orbimed Advisors LLC transactions in Passage Bio, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 10,124,576 shares of PASG stock, worth $6.88 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
10,124,576
Previous 10,124,576
-0.0%
Holding current value
$6.88 Million
Previous $13.7 Million
41.48%
% of portfolio
0.19%
Previous 0.31%
Shares
4 transactions
Others Institutions Holding PASG
# of Institutions
46Shares Held
32.7MCall Options Held
8.3KPut Options Held
400-
Vestal Point Capital, LP New York, NY6.05MShares$4.12 Million0.36% of portfolio
-
Versant Venture Management, LLC San Francisco, CA4.03MShares$2.74 Million7.06% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.7 Million2.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$1.41 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.5MShares$1.02 Million0.14% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $37M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...